Hearing sensitivity in women following chemotherapy treatment for breast cancer: Results from a pilot study

Breast

Volumn 18, Issue 5, 2009, Pages 279-283

  Jenkins, V ^a   Low, R ^b   Mitra, S ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b Worthing Hospital   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Hearing thresholds; Sensorineural hearing loss

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN; FLUOROURACIL; GOSERELIN; TRASTUZUMAB;

ADULT; ARTICLE; AUDITORY SYSTEM FUNCTION; AUDITORY THRESHOLD; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; ESTROGEN BLOOD LEVEL; FEMALE; HEARING ACUITY; HEARING IMPAIRMENT; HORMONE SUBSTITUTION; HUMAN; OTOSCOPY; PERCEPTION DEAFNESS; PILOT STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; SIDE EFFECT; TYMPANOMETRY;

EID: 71049124881     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.07.004     Document Type: Article

References (14)

1. Kim S.H., Kang B.M., Chae H.D., and Kim C.H. The association between serum estradiol level and hearing sensitivity in postmenopausal women. Obstet Gynecol 99 5 Pt 1 (2002) 726-730
2. Strachan D. Sudden sensorineural deafness and hormone replacement therapy. J Laryngol Otol 110 12 (1996) 1148-1150
3. Hederstierna C., Hultcrantz M., Collins A., and Rosenhall U. Hearing in women at menopause. Prevalence of hearing loss, audiometric configuration and relation to hormone replacement therapy. Acta Otolaryngol 127 2 (2007) 149-155
4. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., and Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100 3 (2006) 273-284
5. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Onc. 24 5 (2006) 910-917
6. Hyppolito M.A., de Oliveira J.A., and Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 263 9 (2006) 798-803
7. Tibaldi C., Pazzagli I., Berrettini S., and De Vito A. A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine. Eur J Cancer 34 7 (1998) 1133-1134
8. Koutras A.K., Mastronikolis N.S., Evans T.R., Papadeas E.S., Makatsoris T., and Kalofonos H.P. Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncol 47 6 (2008) 1171-1173
9. Attili V.S., Bapsy P.P., Anupama G., and Lokanatha D. Irreversible sensorineural hearing loss due to Imatinib. Leuk Res 32 6 (2008) 991-992
10. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Proschel M., and Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7 4 (2008) 12.1-12.21
11. Jenkins V., Beveridge H., Low R., and Mitra S. Atypical hearing loss in women with breast cancer receiving adjuvant treatment. The Breast 15 3 (2006) 448-451
12. Parving A., and Christensen B. Clinical trial of a low-cost, solar-powered hearing aid. Acta Otolaryngol 124 4 (2004) 416-420
13. Kilicdag E.B., Yavuz H., Bagis T., Tarim E., Erkan A.N., and Kazanci F. Effects of estrogen therapy on hearing in postmenopausal women. Am J Obstet Gynecol 190 1 (2004) 77-82
14. Sarafraz M., and Ahmadi K. Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhinolaryngol Ital 28 5 (2008) 239-242